Health Care·Biotechnology·$4.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.41 | N/A | +246.18% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.41 | N/A | +246.18% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management expressed satisfaction with the EPS results but did not provide any guidance for future performance. The focus remains on ongoing projects and developments.
Management highlighted the strong performance in EPS despite the lack of revenue guidance.
There was no specific outlook provided for future quarters.
Amicus Therapeutics reported a significant EPS beat, which indicates better-than-expected profitability. However, the stock fell by 7.3% in reaction to the lack of revenue figures and future guidance. Investors may be concerned about the absence of clarity on revenue growth and overall business direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
DIAMONDBACK ENERGY I
Nov 6, 2017